Ryoo Byung-Hwan – CEO, Yungjin – South Korea
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
Yungjin Pharm. Co., Ltd was established in 1952, has been playing a major role as a forerunner in the Korean pharmaceutical industry for half a century. With the corporate mission of “To relieve the suffering of mankind from diseases with our innovative, effective and safe pharmaceutical products”, Yungjin has contributed to human health not only within Korea, but also through global expansion. As a result, Yungjin has received a total of 25 awards including the President’s Award for Superior Product Development, the Prime Minister’s Award, several Industry Awards, and many more. These accomplishments demonstrate Yungjin’s sustainability and commitment to the development of innovative products and business excellence in both overseas and domestic segments.
Contact Details:
451-20, Cheonho-dong,
Gangdong-gu,
Seoul, Korea
Tel : 82 2 2041 8200
Fax : 82 2 4630 9544
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation…
Dr Jino Park, founder and CEO of P&K Skin Research Centre, offers his assessment of the success of the Korean pharmaceutical industry, and the potential cosmetic products of the future.…
Ji-Young Lee, senior director clinical operations, and general management & business administration Korea of PAREXEL Korea discusses the strengths of Korea’s clinical research environment, and how PAREXEL can leverage its…
* This interview was conducted before GE’s announcement of its divestment of the GE Biopharma business Francis Van Parys, president & CEO of GE Healthcare Korea discusses their ambitions to…
Young Kim, founder and CEO of Synex Consulting Ltd., a consulting firm assisting healthcare companies in introducing and marketing their products on the Korean market, discusses how Synex’s ICC (In-Country…
Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology and rare diseases. She also documents Ipsen’s…
Woosok Lee, CEO of Kolon Pharma, Kolon Life Science and Kolon TissueGene, offers his insights into the potential of their blockbuster product Invossa which could exceed USD five billion of…
Dr Jin San-Yoo, president and CEO of PharmAbcine, lifts the lid on the company’s combination therapy with MSD’s blockbuster oncology treatment Keytruda. Dr Yoo explains the rationale behind his decision…
Professor Dae Ho Lee has been researching and treating Korean cancer patients for more than 20 years and advises the current government on healthcare policy. He breaks down the benefits…
This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will allow imports of medical…
Dr Byung Guk Yang, CEO of Daewoong Bio, explains the challenges the Korean healthcare system is facing and how his experience in the public sector now helps him lead a…
YJ Kim, country manager at BD Korea, discusses the integration of Bard into BD at the local level. He also offers his insights into the challenges of approval and pricing…
See our Cookie Privacy Policy Here
